Key Takeaways
- CAM2038 delivers buprenorphine via monthly subcutaneous injection
- Available in 96 mg and 64 mg monthly doses
- Provides consistent therapeutic levels throughout 30-day cycle
- FDA approval expected in US markets; currently available in Europe
- Call Trust SoCal at (949) 280-8360 for emerging MAT treatment updates
Introduction to CAM2038
CAM2038 is a long-acting subcutaneous buprenorphine injection developed as a more flexible alternative to Sublocade implants. Administered monthly via simple subcutaneous injection, CAM2038 maintains therapeutic buprenorphine levels for 30 days. The medication is currently approved in European, Australian, and New Zealand markets, with FDA approval in the United States expected.
The monthly dosing interval offers practical advantages over daily sublingual buprenorphine and more flexibility than the 6-month implant commitment. Patients receive injections once monthly in office settings, requiring minimal training compared to implantation. This bridges the gap between daily dosing and implant-based therapy.
CAM2038 represents a middle-ground option: longer-acting than daily buprenorphine, more flexible than 6-month implants.
Dosing and Administration Protocol
CAM2038 is available in two strengths: 96 mg/month (matching high-dose buprenorphine) and 64 mg/month (for lower-dose patients). Monthly subcutaneous injections are administered in abdominal, arm, or thigh regions, rotating injection sites to prevent tissue reactions. The injection takes less than one minute and requires minimal clinical training.
Patients typically begin CAM2038 after stabilization on daily buprenorphine. Transition protocols involve overlapping oral and injectable dosing for 1-2 days to ensure therapeutic continuity. Subsequent monthly injections are timed on consistent days (e.g., first Tuesday of each month) for predictable medication management.
Dose Selection Guidelines
Appropriate dosing depends on individual stabilization requirements.
- 64 mg/month: Suitable for patients stable on buprenorphine 8-16 mg daily
- 96 mg/month: Appropriate for patients requiring 16-24+ mg daily
- Dose adjustments: Limited during month; additional oral buprenorphine provided if needed
- Transition timing: New injection must be administered before previous month's effect wanes
Efficacy and Clinical Outcomes
European clinical trials demonstrate CAM2038 efficacy comparable to daily sublingual buprenorphine and superior to placebo. Approximately 70-75% of participants achieve opioid abstinence, with sustained abstinence rates improving over treatment continuation. Patient satisfaction is high due to simplified dosing and reduced medication stigma.
Long-term data from markets where CAM2038 is established show sustained opioid abstinence, improved employment outcomes, and enhanced quality of life metrics. Breakthrough opioid use is manageable with supplemental oral buprenorphine. Treatment retention rates exceed 85% over 12-month periods.
Monthly injections eliminate daily dosing burden while maintaining clinical efficacy. This can significantly improve treatment adherence and life stability.
Advantages and Disadvantages Compared to Other MAT
CAM2038 offers significant advantages over daily buprenorphine, including improved adherence, consistent drug levels, and reduced stigma. Compared to Sublocade implants, monthly injections provide more flexibility (easier discontinuation if needed) and eliminate implant-related surgical concerns. The monthly interval balances efficacy with practical patient convenience.
Potential disadvantages include monthly clinic visits and ongoing injection costs. Unlike implants, CAM2038 requires patient engagement for monthly appointments; missed appointments create gaps in medication. Some patients may prefer the clinical finality of implants, while others appreciate the flexibility of monthly dosing.
CAM2038 vs. Daily Buprenorphine
Both are effective, but with different practical implications.
- Daily: Maximum flexibility; requires strict adherence discipline
- CAM2038: Structured monthly appointments; consistent levels without daily decision-making
- Daily: Cheaper initially; higher long-term costs from clinic visits and missed doses
- CAM2038: Higher medication costs; lower total cost with improved adherence
Side Effects and Safety Management
Injection site reactions are the primary concern with CAM2038, including mild pain, erythema, induration, and occasional hematoma formation. These reactions are typically self-limiting within 24-48 hours. Rotating injection sites minimizes tissue irritation and reaction severity. Serious injection-related complications are rare.
Systemic buprenorphine side effects mirror daily sublingual therapy, including constipation, dry mouth, sexual dysfunction, and sedation. Safety profiles are comparable between formulations. Patients with injection-site phobias may experience anxiety but rarely discontinue therapy for this reason.
Rotate injection sites (abdomen, arms, thighs) monthly to prevent lipodystrophy or tissue damage from repeated injections in same location.
Current Regulatory Status and Access
CAM2038 is approved and available in European Union, United Kingdom, Australia, and New Zealand markets. In the United States, FDA approval is anticipated but not yet granted at the time of writing (February 2025). Clinical trials supporting US approval are ongoing, with regulatory decision expected within 12-24 months.
Access outside approved markets remains limited. Patients interested in CAM2038 may explore clinical trial participation or discuss future availability with providers. Trust SoCal remains informed of emerging MAT options and will offer CAM2038 once approved and available in California.
Staying Informed About FDA Approval
Check reliable sources for CAM2038 FDA approval updates.
- FDA.gov medical product approvals section
- Professional addiction medicine journals and organizations
- Trust SoCal website and provider communications
- Clinical trial registries (ClinicalTrials.gov) for active research
Medical Review Board, MD, ABAM
Medical Director & Reviewer
